Open AccessExperience using intravenous posaconazole in paediatric and young adult oncology patients
Author(s) -
Arathi A Lambrix,
Hope D. Swanson,
Jennifer L. Pauley,
Allison Bragg,
Delia Carias,
Melissa S. Bourque,
Yinmei Zhou,
Cheng Cheng,
William L. Greene,
Gabriela Maron
Publication year - 2020
Publication title -
the journal of antimicrobial chemotherapy/journal of antimicrobial chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.124
H-Index - 194
eISSN - 1460-2091
pISSN - 0305-7453
DOI - 10.1093/jac/dkaa377
Subject(s) - posaconazole , medicine , therapeutic drug monitoring , dosing , adverse effect , body surface area , retrospective cohort study , pharmacokinetics , surgery , pharmacology , antifungal , itraconazole , dermatology
Posaconazole exhibits broad-spectrum antifungal activity. An IV formulation became available in 2014. Few studies describing the use of this formulation exist in patients under the age of 18 years. This study describes our experience using IV posaconazole in paediatric and young adult cancer patients.